About Acorn Biolabs
Acorn Biolabs is a Healthcare company based in Toronto (Canada) founded in 2017 by Steven ten Holder, Laura Vaughan, Patrick Pumputis, and Drew Taylor. It operates as a personalized regenerative medicine solutions are provided by Acorn Biolabs. It operates on a HealthTech and Subscription Services model. Acorn Biolabs has raised $3.33 million across 4 funding rounds from investors including Globalive Capital, TELUS Ventures and Real Ventures. Its chief executive is Drew Taylor. Its website acorn.me draws about 12 thousand monthly visits. Acorn Biolabs offers products and services including Personalized Regenerative Medicine, Stem Cell Banking, and Cell-Derived Topical Treatments. Its focus areas include Biotechnology and Regenerative Medicine. Its competitors include StemCyte, China Cord Blood, Generate, LaCell and Forever Labs and 1 more; 3 of its 6 listed competitors have raised funding.
Company details
Acorn Biolabs is focused on personalized regenerative medicine by preserving stem cells for future treatments. Services are offered in the healthcare sector, targeting skin rejuvenation, hair regrowth, injury recovery, and disease treatment. Innovative solutions are developed using cryopreservation of clients own cells to halt aging effects. The potential of regenerative therapies is explored to address aging, injuries, and chronic conditions through advanced biotechnological approaches.
- Total Equity Funding$3.33M (USD)
in 4 rounds
- InvestorsGlobalive Capital
& 5 more
Products & Services of Acorn Biolabs
Acorn Biolabs offers a comprehensive portfolio of products and services, including Personalized Regenerative Medicine, Stem Cell Banking, and Cell-Derived Topical Treatments.
Stem cells are preserved for personalized regenerative treatments.
Cells are cryogenically frozen to halt aging effects.
Topical treatments are developed using preserved stem cells.
Funding Insights of Acorn Biolabs
Acorn Biolabs has successfully raised a total of $3.33M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.33M
- Total Rounds 4
- First Round $30,000
(Jun 2017)
- Investors Count 6
All 4 funding rounds of Acorn Biolabs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | – | Series A | – | – | – |
| Apr 2019 | – | Seed | – | TELUS Ventures | – |
| Jan 2019 | $3.3M | Seed | – | – | |
| Jun 2017 | $30,000 | Seed | – | Accelerator Centre | – |
6 investors in total: 6 institutional.
Investors in Acorn Biolabs
Acorn Biolabs has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Globalive Capital, TELUS Ventures and Real Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in multiple sectors are directed by TELUS Ventures. | – | telus.com/ventures | Vancouver, Canada | |
Early-stage venture capital is provided to Canadian technology startups by Real Ventures. | – | realventures.com | Montreal, Canada | |
- | – | poolglobalpartners.com | - | |
- | – | epiccapitalmanagement.ca | - | |
Venture capital is provided to Canadian tech and offline companies. | 1998 | globalive.com | Toronto, Canada | |
Startups are built and accelerated in a structured studio environment. | – | acceleratorcentre.com | Waterloo, Canada |
Investor details for Acorn Biolabs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acorn Biolabs
12 people are tracked at Acorn Biolabs (8 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Steven ten Holder | Co-Founder & COO | Leadership |
Laura Vaughan | Co-Founder & CTO | Leadership |
Patrick Pumputis | Co-Founder & CSO | Leadership |
Drew Taylor | Co-Founder & CEO | Leadership |
William Hall | Chief Operating Officer | Leadership |
Amatullah Fatehi | Director Of Laboratory Science | Leadership |
Amanda May Post | Director Of Training And Development | Leadership |
Crystal Cienfuegos Muilenburg | Chief Commercial Officer | Leadership |
Christopher Duhyun Han | Lab Manager | Team |
Brienne Owens | Operations Sales Manager NA | Team |
Muneera Fayyad | Lead Scientist | Team |
James McDaniel III | Lab Manager | Team |
Complete people profiles for Acorn Biolabs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Acorn Biolabs
3 dated milestones of Acorn Biolabs across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Acorn Biolabs is founded.
- Funding First funding round of $30K.
- Funding Latest funding round, Series A,.
Competitors of Acorn Biolabs
Acorn Biolabs has 6 listed competitors in our database, 3 of them funded. They include StemCyte, China Cord Blood, Generate, LaCell and Forever Labs, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stemcyte.com | 1997 | Covina, United States | $23.25M | 43 | Umbilical cord blood stem cell transplantation and therapeutic products company | |
| globalcordbloodcorp.com | 2003 | Hong Kong, China | – | – | Biobanking services for umbilical cord blood stem cells are provided. | |
| generate.com | 1977 | Los Angeles, United States | – | – | Provider of services for the storage of stem cells | |
| lacell-usa.com | 2010 | New Orleans, United States | – | – | Stem Cell Production | |
| foreverlabs.com | 2015 | Detroit, United States | $2.22M | 9 | Stem cells are stored and preserved for future therapeutic applications. | |
| provialabs.com | 2009 | Littleton, United States | $1M | 15 | Stem cell biobanking and manufacturing from children's teeth are provided. |
Detailed competitors of Acorn Biolabs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acorn Biolabs
The website of Acorn Biolabs (acorn.me) receives about 12.4K visits a month.
- Monthly visits12.4K
▲ 47.6% vs previous month
Websites whose visitors overlap most with Acorn Biolabs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
raisingnad.com | raisingnad.com | 100% | – | #1,364,590 | – |
shop.drdrew.com | shop.drdrew.com | 97% | – | #8,423,815 | – |
biogen.ca | biogen.ca | 84% | – | #3,584,714 | – |
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Acorn Biolabs (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acorn Biolabs
Complete news archive for Acorn Biolabs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acorn Biolabs
Acorn Biolabs was founded in 2017.
Acorn Biolabs is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Drew Taylor is the current CEO of Acorn Biolabs. They have also founded this company.
Acorn Biolabs is a funded company, having raised a total of $3.33M across 4 funding rounds to date. The company's 1st funding round was a Seed of $30K, raised on Jun 2017.
Acorn Biolabs is focused on personalized regenerative medicine by preserving stem cells for future treatments. Services are offered in the healthcare sector, targeting skin rejuvenation, hair regrowth, injury recovery, and disease treatment. Innovative solutions are developed using cryopreservation of clients own cells to halt aging effects. The potential of regenerative therapies is explored to address aging, injuries, and chronic conditions through advanced biotechnological approaches.
Acorn Biolabs's top competitors include StemCyte, Forever Labs and China Cord Blood.
Acorn Biolabs offers Personalized Regenerative Medicine, Stem Cell Banking, and Cell-Derived Topical Treatments.
Acorn Biolabs has 6 investors. Key investors include Globalive Capital, TELUS Ventures, Real Ventures, Pool Global Partners, and Epic Capital Management.